• OMRON Ventures joins existing investors abrdn, Environmental Technologies Fund and consortium led by Granpool Innovative Investments 
• Scale-up focused on enabling novel, sustainable scientific innovations that harness the  microbiome to solve for ‘One Health’ challenges, through development of AI-augmented knowledge discovery platform, e[datascientist]™ 

CAMBRIDGE, UK – 16 January 2023 – Today, Eagle Genomics, the pioneering TechBio platform business  applying network science¹ to biology, disclosed additional scale-up funding from Japan-based corporate  venture capital firm OMRON VENTURES CO., LTD. The funds will support the ongoing development of Eagle  Genomics’ e[datascientist]^{™ 2} platform as well as continued global expansion and increased client impact. The  e[datascientist]™ uses multilayer hypergraphs to structure and interrogate data, applying AI to network  science to derive data-driven insight journeys into complex problems at scale. The current funding round is  ongoing, and open for additional investment opportunities. 

Eagle Genomics continues to mature and expand as the leading TechBio company pioneering the application  of network science to biological discovery and innovation, across the Food and Nutrition, AgBio, Beauty and  Personal Care, and Biopharma industries. The e[datascientist] platform enables enterprise customers to trace  digital journeys in data, drive transformative innovations, exploit leading-edge scientific discovery in silico and  support differentiated product claims. By networking scientific data to support step-change innovation, Eagle  Genomics is bridging the ‘translation gap,’ using scientific knowledge from a range of disparate sources and  studies across industries to deliver robust, scientifically underpinned product claims.³ 

The company’s partners include household names like Unilever, where research on the skin and oral  microbiome, powered by Eagle Genomics’ platform resulted in the development of products and claims  relating to the improvement and maintenance of skin and oral health, such as Zendium toothpaste and Dove  soap. 

As such, Eagle Genomics values supporting its customers’ aspirations as they address ‘One Health’ ⁴ challenges  towards more sustainable and impact-oriented innovation. A knowledge of the microbiome, and host microbiome interactions across human, animal, and environmental health domains is critical to unlocking  radical innovation opportunities that can solve these challenges. This is where the e[datascientist]’s  capabilities to efficiently interrogate multi-dimensional microbiome and other biological data plays an  invaluable role. 

Anthony Finbow, CEO, Eagle Genomics, said:

“We are the pre-eminent platform business using next generation graph technology and network science to drive the Bioeconomy. We support our enterprise  customers to achieve more sustainable and impact-orientated innovation outcomes by harnessing the knowledge of the microbiome. This is especially important in areas of unmet clinical need, such as metabolic  health and cardiovascular health where the microbiome’s effect is becoming increasingly more prevalent and  critical. The current scale-up funding from OMRON Ventures will further our transformational impact across  these very important domains and others across One Health domains.” 

Tomoko Inoue, CEO, OMRON VENTURES Co., LTD., said:

“In today’s society, which is overflowing with data,  OMRON Ventures strives to create new value by leveraging data as an asset. Eagle Genomics and its  e[datascientist] platform enables innovation journeys that can yield differentiated products, product claims,  and asset repurposing. Its focus on influencing systems-change and data-driven innovation to accelerate the Bioeconomy aligns closely with our principles for social and economic change. We are therefore very pleased  to be making our current investment in Eagle Genomics and wish it all the best on its upwards trajectory.”

In October 2022, Eagle Genomics announced a USD $20 million first close of its scale-up funding round. The  round was led by abrdn plc, with continued participation from existing investors Environmental Technologies  Fund, and a consortium of investors headed by Granpool Innovative Investments. 

Notes 

1. Network science is the study of complex networks of physical, biological, and social phenomena, and can also be used to explain and deeply  understand these phenomena.  

2. The e[datascientist]™ is powered by network science and multilayer hypergraphs, applying machine learning and AI to provide a data-driven  insight journey into solving complex problems at scale. It integrates active learning at every step of the microbiome innovation journey, from  ‘descriptive’ to ‘predictive,’ while identifying mechanisms of action. It has been gaining major traction with large household brands as they strive to  demonstrate the link between their latest products, microbiome health, and ‘One Health’ related issues.  

3. Innovation journeys that enable differentiated products and product claims include:  

Food and Nutrition: Personalised and functional nutrition, e.g., energy balance, feed efficiency, growth rate, botanicals, food as medicine, precision  fermentation, alternative proteins and ingredient design and differentiation. 

Beauty and Personal Care: Personalised/stratified cosmetics, e.g., skin, oral, scalp, pre/pro/postbiotics, ingredient manufacturing, cosmeceuticals,  and genital health/personal hygiene products. 

AgBio: Biofertilizers, microbiome engineering, bioavailability, crops (yield increase, protection, fertility, productivity, climate adaptation/change  mitigation), soil treatment, and smart agriculture. 

BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious  diseases, immuno-oncology/autoimmune disease, and metabolic health. 

4. One Health recognises that the health of humans, animals, and the environment are intimately interconnected and that applying technologies to  solve in one domain can inspire and enable advances in others. 

– ENDS – 

Notes to Editors 

About Eagle Genomics  

Eagle Genomics is innovating at the intersection of biology, data sciences and bioinformatics, to accelerate the Bioeconomy  through the digital reinvention of life sciences R&D. The company’s award-winning AI-augmented knowledge discovery  platform, e[datascientist]™, empowers scientists to exploit multi-dimensional data in minutes rather than months, to help  companies conduct science-led innovation for next-generation products. It supports the entire innovation workflow – from  hypothesis through insight to product claims – helping bring novel, safer and sustainable products to market, faster, across  the Food and Nutrition, Beauty and Personal Care, AgBio and BioPharma industries.  

Eagle Genomics is forging strategic relationships with leading scientific establishments focused on the microbiome and has  helped shape the Microbiome Strategic Roadmap in the UK. A Cambridge, UK-headquartered business with a global  presence, it has sites in London’s Knowledge Quarter, Hyderabad India, New York’s Genome Center as well as Paris’ Station  F, Potsdam Science Park, Germany and Kyiv, Ukraine.  

Find out more at www.eaglegenomics.com 

About OMRON VENTURES CO., LTD. 

OMRON VENTURES CO., LTD. is a corporate venture capital established to create innovation driven by social needs by  investing and engaging in joint development with startups from around the globe with original technologies and ideas, with  a view toward offering solutions to social issues laid out in OMRON’s Medium- to Long-Term Vision SF2030. Currently,  focus domains for its investments include FA, smart cities, digital health, and energy management. For details, please visit  https://www.omron.com/omronventures/en/.